Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

parathyroid hormone

- PMLiVE

J&J fast-tracks Ebola vaccine

Human clinical trials set to begin in early 2015

Novartis building

Novartis heart failure trial leads the buzz at ESC

Potential blockbuster LCZ696 cuts cardiovascular deaths by 20% versus standard therapy

Novartis building

Novartis licenses tuberculosis R&D to TB Alliance

Includes drugs to tackle resistant forms of the disease

Novartis building

Novartis will file heart failure drug before year-end

New data reinforces view that LCZ696 can reduce cardiovascular deaths

- PMLiVE

FDA approves J&J’s diabetes combo

Invokamet combines Invokana and metformin to help reduce blood sugar

EU flag

International regulators collaborate on generics

EMA leads three-year pilot project to increase pre-market data sharing

- PMLiVE

Amgen closes on second-line use for Kyprolis

Multiple myeloma therapy posts positive interim phase III results

Novartis building

Novartis: novel antimalarial is ‘game-changing’

Says cipargamin could be first new class of malaria drugs in 20 years

- PMLiVE

NICE set to block post-Velcade use of Revlimid

Watchdog's new draft guidance does not recommend Celgene blood cancer drug

Novartis building

Novartis’ glaucoma combo cleared in Europe

Simbrinza approved to treat eye condition

- PMLiVE

Neupogen will be first biologic on FDA biosimilars pathway

US regulator will review Novartis’  version of Amgen's Neupogen (filgrastim) over the coming months

- PMLiVE

It’s on: Shire and AbbVie agree £32bn takeover

Companies agree deal that is set to cut US pharma company’s corporate tax bill

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links